The NeurologyLive® neuromuscular disease clinical focus page offers updates and information related to the clinical care and management of individuals with neuromuscular diseases such as amyotrophic lateral sclerosis, Duchenne muscular dystrophy, cerebral palsy, and spinal muscular atrophy, as well as rare diseases. This page consists of news, podcasts, and videos about the latest FDA actions, clinical guideline updates, interviews with physicians, study and clinical trial findings, and more.

Latest News

Ianalumab Meets Primary End Points in Phase 3 NEPTUNUS Trials of Sjögren’s Disease
Ianalumab Meets Primary End Points in Phase 3 NEPTUNUS Trials of Sjögren’s Disease

August 12th 2025

Novartis revealed promising phase 3 trial results for ianalumab, a potential first treatment for Sjögren’s disease, showing significant disease activity reduction.

FDA Action Update, July 2025: Approval, Label Update, Complete Response Letter
FDA Action Update, July 2025: Approval, Label Update, Complete Response Letter

August 12th 2025

This Week on NeurologyLive® — August 11, 2025
This Week on NeurologyLive® — August 11, 2025

August 11th 2025

Openwater’s LIFU Technology at MIT: A New Era for Consciousness and Neurological Care
Openwater’s LIFU Technology at MIT: A New Era for Consciousness and Neurological Care

August 7th 2025

NaV1.8 Pain Signal Inhibitor VX-993 Fails to Show Efficacy in Phase 2 Trial of Acute Pain
NaV1.8 Pain Signal Inhibitor VX-993 Fails to Show Efficacy in Phase 2 Trial of Acute Pain

August 7th 2025

Video Series
Video Interviews
Podcasts
Latest CME Events & Activities

More News

© 2025 MJH Life Sciences

All rights reserved.